



UNIVERSITY OF LEEDS

This is a repository copy of *The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/116583/>

Version: Supplemental Material

---

**Article:**

Mackie, SL, Twohig, H, Neill, LM et al. (10 more authors) (2017) The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. *Journal of Rheumatology*, 44 (10). 161109. pp. 1515-1521. ISSN 0315-162X

<https://doi.org/10.3899/jrheum.161109>

---

© 2017 The Journal of Rheumatology. This is a pre-copy-editing, author-produced PDF of an article accepted for publication in *The Journal of Rheumatology* following peer review. The definitive publisher-authenticated version, Mackie, et al. (2017) *The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica*. *Journal of Rheumatology*, 44. 161109, is available online at:  
<https://doi.org/10.3899/jrheum.161109>.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

**Table 2. Results from Rounds 1 and 2 of Delphi study of core domains for polymyalgia rheumatica.**

<b>Domain</b>	<b>Round 1 Clinicians (n=60), %</b>	<b>Round 1 Patients (n=55), %</b>	<b>Round 2 Clinicians (n=55), %</b>	<b>Round 2 Patients (n=46), %</b>
Pain/ache	<b>90</b>	<b>78</b>	-	-
Stiffness severity	56	56	53	<b>74</b>
Morning stiffness duration	68	36	<b>85</b>	43
Muscle weakness	12	53	-	<b>80</b>
Fatigue / tiredness	49	<b>73</b>	65	-
Sleep disturbance	10	35	-	57
Mood problems – low or “high”	3	20	-	37
Anxiety	3	33	-	30
Weight loss/gain	25	33	27	48
Appetite loss/gain	3	11	-	-
Balance problems	2	7	-	-
Fevers/shivers/sweats/flu like symptoms	12	15	-	-
Ability to do everyday activities	51	55	65	<b>74</b>
Lack of mobility	25	35	7	59
Dependence on stick, wheelchair, etc.	0	2	-	-
Dependence on other people	5	9	-	-
Ability to carry out usual roles (work, caring for others, etc.)	20	35	16	37
Health-related quality of life	50	24	76	39
Overall quality of life	27	51	13	<b>72</b>
Change in appearance of face or body	8	22	-	41
Fluid retention / ankle swelling	2	9	-	-
Bruising, poor healing or other skin change	5	24	-	50
Doctor’s assessment of activity/severity of PMR	59	60	<b>71</b>	83
Patient’s assessment of activity/severity of PMR	<b>76</b>	42	-	<b>76</b>
Blood tests	<b>86</b>	40	-	<b>70</b>
Abnormalities identified by physical examination	22	7	20	-

by a doctor				
Abnormalities identified by imaging tests	36	20	29	33
Bone fragility	27	13	29	-
New or worsening diabetes mellitus	14	5	-	-
High blood pressure	12	11	-	-
Cost of treatments used in the study	31	18	13	-
Overall costs to the healthcare provider	36	24	22	11
Overall costs to society	56	40	55	20
Any glucocorticoid-related adverse effect in judgement of doctor	-	-	46	63
Any glucocorticoid-related adverse effect in judgement of patient	-	-	23	80

Numbers given are percentages of respondents selecting each outcome. Domains with >70% agreement are highlighted in bold; for each group (clinicians or patients) only domains with 20-69% agreement in round 1 went forward to Round 2. Bold denotes that with >70% agreement from either group in Round 1 or Round 2, the domain went forward into the combined Round 3. "-" denotes that the question was not asked in that round.

PMR: polymyalgia rheumatica